Open AccessMechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report
Author(s) -
Yuri Ozaki,
Ashio Yoshimura,
Masataka Sawaki,
Masao Hattori,
Naomi Gondo,
Hirokazu Kotani,
Yayoi Adachi,
Ayumi Kataoka,
Kayoko Sugino,
Nanae Horisawa,
Yuka Endo,
Kazuki Nozawa,
Shoko Sakamoto,
Hiroji Iwata
Publication year - 2020
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v11.i7.504
Subject(s) - medicine , bevacizumab , pneumothorax , surgery , lung cancer , bronchopleural fistula , perforation , gastrointestinal perforation , adverse effect , thoracic cavity , pleural cavity , pleurodesis , lung , chemotherapy , pneumonectomy , dehiscence , oncology , materials science , metallurgy , punching
Bevacizumab is an antiangiogenic agent, and that synergizes with chemotherapeutic drugs. When used in combination therapies, Bevacizumab is associated with adverse events such as hemorrhage, gastrointestinal perforation, delayed wound healing, and pneumothorax. However, the molecular mechanisms underlying these adverse events are not fully understood.